Sign In
Buy DGX
$235.84
+2.12 (+0.91%)
At Close: Aug 05, 2026
Quest Diagnostics (DGX) Boosts Oncology Portfolio With New Test
09:01am, Thursday, 15'th Feb 2024
Quest Diagnostics (DGX) debuts the MelaNodal Predict test in collaboration with SkylineDx.
Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering
09:21am, Tuesday, 13'th Feb 2024
Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.
3 Medtech Stocks Likely to Top Estimates This Earnings Season
08:51am, Tuesday, 13'th Feb 2024
Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
08:16am, Tuesday, 06'th Feb 2024
Strength of the base business bodes well for Quest Diagnostics (DGX).
Quest Diagnostics: Post-COVID Normalization Pretty Much Done
05:36am, Monday, 05'th Feb 2024
Quest Diagnostics is a leading provider of diagnostic information services, offering laboratory testing, genomics, and other diagnostic solutions. During 2020, COVID-19 detection tests played an impor
Quest Diagnostics Inc. (DGX) Q4 2023 Earnings Call Transcript
11:42am, Thursday, 01'st Feb 2024
Quest Diagnostics Inc. (DGX) Q4 2023 Earnings Call Transcript
Quest Diagnostics (DGX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
10:37am, Thursday, 01'st Feb 2024
Although the revenue and EPS for Quest Diagnostics (DGX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with
Quest Diagnostics (DGX) Q4 Revenues Top, Gross Margin Down
10:31am, Thursday, 01'st Feb 2024
Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the fourth quarter of 2023.
Quest Diagnostics (DGX) Q4 Earnings and Revenues Beat Estimates
08:56am, Thursday, 01'st Feb 2024
Quest Diagnostics (DGX) came out with quarterly earnings of $2.15 per share, beating the Zacks Consensus Estimate of $2.14 per share. This compares to earnings of $1.98 per share a year ago.
Quest Diagnostics (DGX) Advances in Cancer Research With New Deal
10:16am, Friday, 26'th Jan 2024
Quest Diagnostics' (DGX) subsidiary Haystack Oncology collaborates with TriSalus Life Sciences to improve therapeutic options for aggressive forms of cancer.
Oncology Space Gains Momentum: 3 Stocks in Focus
10:50am, Tuesday, 23'rd Jan 2024
Stocks such as EXAS, DGX and LH are likely to potentially continue the momentum in the oncology field.
3 Discounted MedTech Stocks Poised for Sturdy Growth in 2024
12:26pm, Friday, 19'th Jan 2024
Prestige Consumer Health (PBH), Quest Diagnostics (DGX) and Hologic (HOLX) are currently at discounted zone that are expected to provide long-term gains.
Quest Diagnostics (DGX) and Fitbit Team Up for New Pilot Study
08:26am, Friday, 19'th Jan 2024
Quest Diagnostics (DGX) partners with Fitbit to study the potential of wearable devices to improve metabolic health.
The Top 3 Stocks in the High-Potential ‘Cancer Testing' Market
05:04am, Thursday, 18'th Jan 2024
Blood tests for dozens of types of cancer have been invented. These tests, known as liquid biopsies, could save tens of millions of lives.
Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024
09:35am, Wednesday, 17'th Jan 2024
SECAUCUS, N.J. , Jan. 17, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that it will report fourth quarte
